Literature DB >> 29437061

Mid-term follow-up of patients with hindfoot arthrodesis with retrograde compression intramedullary nail in Charcot neuroarthropathy of the hindfoot.

M Chraim1, S Krenn1, H M Alrabai2, H-J Trnka3, P Bock1.   

Abstract

AIMS: Hindfoot arthrodesis with retrograde intramedullary nailing has been described as a surgical strategy to reconstruct deformities of the ankle and hindfoot in patients with Charcot arthropathy. This study presents case series of Charcot arthropathy patients treated with two different retrograde intramedullary straight compression nails in order to reconstruct the hindfoot and assess the results over a mid-term follow-up. PATIENTS AND METHODS: We performed a retrospective analysis of 18 consecutive patients and 19 operated feet with Charcot arthropathy who underwent a hindfoot arthrodesis using a retrograde intramedullary compression nail. Patients were ten men and eight women with a mean age of 63.43 years (38.5 to 79.8). We report the rate of limb salvage, complications requiring additional surgery, and fusion rate in both groups. The mean duration of follow-up was 46.36 months (37 to 70).
RESULTS: The limb salvage rate was 16 of 19 limbs. Three patients had to undergo below-knee amputation due to persistent infection followed by osteomyelitis resistant to parenteral antibiotic therapy and repeated debridement. Complications including infection, hardware removal, nonunion, and persistent ulcers requiring further intervention were also observed. Postoperative functional scores revealed significant improvement compared with preoperative scores on American Orthopaedic Foot and Ankle Society (AOFAS) - Hindfoot scale, Foot Function Index (FFI), visual analogue scale (VAS), and Foot and Ankle Outcome Score (FAOS).
CONCLUSION: The use of retrograde intramedullary compression nail results in good rates of limb salvage when used for hindfoot reconstruction in patients with Charcot arthropathy. Cite this article: Bone Joint J 2018;100-B:190-6. ©2018 The British Editorial Society of Bone & Joint Surgery.

Entities:  

Keywords:  Ankle fusion; Charcot arthropathy; Diabetes mellitus; Hindfoot arthrodesis; Subtalar joint; Tibiotalar joint; Tibiotalocalcaneal nail

Mesh:

Year:  2018        PMID: 29437061     DOI: 10.1302/0301-620X.100B2.BJJ-2017-0374.R2

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


  6 in total

1.  High rate of complications after corrective midfoot/subtalar arthrodesis and Achilles tendon lengthening in Charcot arthropathy type Sanders 2 and 3.

Authors:  Markus Regauer; Veronika Grasegger; Julian Fürmetz; Adrian Calvacanti Kussmaul; Wolfgang Böcker; Christian Ehrnthaller
Journal:  Int Orthop       Date:  2022-09-22       Impact factor: 3.479

2.  Clinical evaluation of tibiocalcaneal arthrodesis with retrograde intramedullary nail fixation in diabetic patients.

Authors:  Raffaele Vitiello; Andrea Perna; Marco Peruzzi; Dario Pitocco; Galli Marco
Journal:  Acta Orthop Traumatol Turc       Date:  2020-05       Impact factor: 1.511

3.  Current concepts and challenges in managing ankle fractures in the presence of diabetes: A systematic review of the literature.

Authors:  William J Nash; Thomas Hester; Joon Ha
Journal:  J Clin Orthop Trauma       Date:  2021-02-03

4.  Charcot foot reconstruction outcomes: A systematic review.

Authors:  Joon Ha; Thomas Hester; Robert Foley; Ines L H Reichert; Prashanth R J Vas; Raju Ahluwalia; Venu Kavarthapu
Journal:  J Clin Orthop Trauma       Date:  2020-04-20

5.  Charcot Neuroarthropathy: Current Surgical Management and Update. A Systematic Review.

Authors:  Mohd Yazid Bajuri; Shir Lee Ong; Srijit Das; Isa Naina Mohamed
Journal:  Front Surg       Date:  2022-03-08

6.  Mid-term results of hindfoot arthrodesis with a retrograde intra-medullary nail in 24 patients with diabetic Charcot neuroarthropathy.

Authors:  Mehmet Ersin; Mehmet Demirel; Mehmet Chodza; Fuat Bilgili; Onder Ismet Kiliçoglu
Journal:  Acta Orthop       Date:  2020-04-01       Impact factor: 3.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.